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Abstract 
Effective treatment regimens for elderly acute myeloid leukemia (AML) patients harboring 
internal tandem duplication mutations in the FLT3 kinase gene (FLT3/ITD) are lacking and 
represent a significant unmet need.  Recent data on the effects of FLT3 tyrosine kinase inhibitors 
on FLT3/ITD+ AML showed promising clinical activity, including in elderly patients.  DNA 
methyltransferase (DNMT) inhibitors such as decitabine (DEC) and 5-azacitidine (AZA) 
demonstrated clinical benefit in AML, are well tolerated, and are associated with minimal 
increases in FLT3 ligand, which can represent a potential resistance mechanism to FLT3 
inhibitors.  In addition, both FLT3 and DNMT inhibition are associated with the induction of 
terminal differentiation of myeloid blasts. Consequently, there is a strong theoretical rationale for 
combining FLT3 and DNMT inhibition for FLT3/ITD+ AML.  We therefore sought to study the 
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anti-leukemic effects of DEC, AZA and FLT3 inhibitors, either as single agents or in 
combination, on AML cell lines and primary cells derived from newly diagnosed and relapsed 
AML patients.  Our studies indicate that combined treatment using FLT3 inhibition and 
hypomethylation confers synergistic anti-leukemic effects, including apoptosis, growth 
inhibition, and differentiation.  The simultaneous administration of 5-azacitidine and FLT3 
inhibition appears to be the most efficacious combination in this regard.  These drugs may 
provide a novel therapeutic approach for FLT3/ITD+ AML, particularly for older patients. 
 
Introduction 
Internal tandem duplication mutations in the receptor tyrosine kinase FMS-Like Tyrosine 
Kinase-3 (FLT3/ITD mutations) are present in a substantial proportion of AML patients of all 
age groups and have been shown to be an important negative prognostic indicator of disease 
outcome, as mirrored in high relapse and poor survival rates(1). The poor prognostic impact, 
along with the observation that FLT3 is frequently overexpressed in the majority of AML cases, 
has formed the platform for the development of FLT3-targeted strategies.  To date, several FLT3 
kinase inhibitors have been investigated in pre-clinical and clinical studies(2). Agents such as 
quizartinib (formerly AC220) and sorafenib demonstrated selectivity and potency in cell culture 
assays and animal models(3, 4). Recently, Sexauer et al. demonstrated that inhibition of FLT3 
signaling with either quizartinib or sorafenib results in rapid clearance of peripheral blasts by 
induction of apoptotic cell death and terminal myeloid differentiation of bone marrow blasts, 
which, in most cases, is clinically represented by a surge of leukemia-derived neutrophils 
occurring 30 to 60 days after initiation of treatment(5). Others have shown similar findings for 
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patients treated with FLT3 inhibitors(6-8). Despite the fact that FLT3 inhibitors induce clinical 
remissions in the majority of patients, drug resistance is frequently encountered within the first 
12 months of treatment, either due to acquired mutations in the tyrosine kinase domain (TKD) of 
FLT3, increases in FLT3 ligand (FL) levels, or through other incompletely understood 
mechanisms(7, 9, 10). In order to improve the therapeutic outcome for treatment-naive and -
resistant FLT3/ITD+ AML several strategies, including combination therapy with traditional 
chemotherapeutic regimens and allogeneic stem cell transplant (SCT), have been employed(11-
13). While younger patients with FLT3/ITD+ AML seem to benefit from allogeneic SCT, this is 
frequently not an option for many older patients due to preexisting comorbidities and the 
inability to tolerate intensive induction and consolidation protocols.  Hence, effective treatment 
approaches for elderly patients are lacking and represent a significant unmet need in this field. 
In recent years, therapeutic approaches targeting epigenetic changes in hematologic 
malignancies have received considerable attention in light of the potential role of these 
alterations in leukemogenesis(14, 15). To this end, the cytidine derivatives and DNA 
methyltransferase inhibitors (DNMTis) decitabine (5-aza-2-deoxycytidine, DEC) and azacitidine 
(5-azacytidine, AZA) have shown anti-leukemic potential in several preclinical and clinical 
studies, largely mediated by inhibition of proliferation, induction of apoptosis, and myeloid 
differentiation(16-19). Importantly, these agents do not appear to induce large magnitude 
increases in FL levels and are therefore unlikely to hinder the effects of FLT3 inhibitors(20). 
DEC and AZA confer their epigenetic effects by incorporating into newly formed DNA where 
they irreversibly bind to DNA-methyltransferases in an S-phase dependent fashion.  Notably, 
besides being converted to decitabine triphosphate and subsequent incorporation into DNA, the 
majority of AZA (approximately 80-90%) is incorporated into RNA, thereby disrupting nucleic 
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acid and protein synthesis(21). It has been suggested that these additional effects of AZA 
contribute to the different outcomes between DEC and AZA observed in clinical trials (22-24), 
although the exact mechanisms have not yet been clearly defined.     
Due to their different modes of action but similar, and partially complementary, effects 
on leukemic blasts, there is a strong theoretical rationale to combine FLT3 inhibitors with 
DNMTis.  Single arm studies combining AZA with either sorafenib or quizartinib have recently 
been carried out and demonstrated both safety and a promising response rate in FLT3/ITD AML 
patients(20, 25). In the present study, we investigated the effects of DEC and AZA on AML cell 
lines and primary cells to determine if the combination of either drug with FLT3 inhibition bears 
synergistic anti-leukemic potential, and, if so, which drug and which sequence of administration 
would be most effective.  Our findings suggest that AZA administered simultaneously with 
FLT3 inhibition leads to the highest degree of anti-leukemic activity, as manifest by inhibition of 
growth and induction of both apoptosis and differentiation.  This represents a novel approach to 
target FLT3/ITD mutated AML, particularly in elderly AML patients. 
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Methods 
Cell culture and reagents 
AML cell lines and primary blasts were cultured as previously described(26).  Molm14 cells 
were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ; 
Braunschweig, Germany).  Quizartinib and sorafenib (LC labs Woburn, MA) was dissolved in 
dimethyl sulfoxide (DMSO) at stock concentrations of 10 mM.  DEC and AZA were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in phosphate-buffered saline (PBS) to 
stock concentrations of 5 mM and 10 mM and stored at - 20˚C.  Depending on the incubation 
period for each experiment, quizartinib or sorafenib was added every 5 days, and DEC and AZA 
were added every 24 hours.  L-glutamine and Penicillin/Streptomycin were purchased from 
Invitrogen (Carlsbad, CA, USA).  Hydrocortisone was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). 
The following antibodies were used for Western blotting: Anti-phosphotyrosine clone 4G10 
(Millipore), FLT3 (S-18, Santa Cruz), and beta-actin (#4967, Cell Signaling Technologies).  The 
following antibodies used for flow cytometry were obtained from BD Pharmingen: CD34-FITC 
(#555821), CD117-PE (#340529), FITC-Annexin V (#556419), and Propidium Iodide 
(#556463). 
 
Patient samples  
AML blasts from whole blood or bone marrow of newly diagnosed (ND) and relapsed (REL) 
FLT3/ITD mutated patients and bone marrow aspirates from healthy donors were collected and 
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banked separately as part of an institutional protocol supported by the Regional Oncology 
Research Center Grant # 2 P30 CA 006973-44.  All patients gave informed consent according to 
the Declaration of Helsinki.  Blasts were separated by centrifugation over a layer of Ficoll-paque 
PLUS (GE Healthcare, Fairfield, CT, USA), collected as the buffy coat and then either stored in 
freezing medium (fetal bovine serum [FBS] with 10% DMSO) in liquid nitrogen or plated 
immediately for experiments.  The clinical characteristics of the patients from whom samples 
were derived are listed in Supplemental Table 1. For the experiments involving patient blasts 
incorporated into figure 2, three replicates were performed (n = 3), and the differentiation 
experiments (n = 3 for samples from different patients) were exploratory and dependent upon 
patient sample availability and cell yield. 
 
Bone marrow stromal culture 
Normal human bone marrow stroma was harvested from patients as previously described(5).   
Mononuclear cells were isolated via centrifugation with Ficoll-Paque PLUS (GE Healthcare Life 
Sciences), plated into T75 flasks, and incubated in stromal medium (RPMI  1640/ 10%FBS/ 1% 
L-glutamine, 1% Penicillin/Streptomycin, 1μmol/l hydrocortisone) at 33˚C in 5% CO2.  The first 
media change was performed 24-48 hours after the initial plating, and every subsequent media 
change was performed every 1-2 weeks.  Once the adherent stromal cells growing in the flasks 
were at least 80% confluent, cells were passaged using Trypsin-EDTA (Sigma) to be plated into 
6-, 12-, or 96-well plates and T75 flasks.  
 
MTT Cell viability assays 
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Cell growth and cytotoxicity were assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Roche, Indianapolis, USA) in accordance to the 
manufacturer’s recommended protocols in the presence and absence of inhibitors as outlined for 
each experiment.  When performing assays with bone marrow stromal co-culture, approximately 
8000 stromal cells/well were seeded in 96-well plates. For MTTs with both cell lines and patient 
blasts (Figs. 1-2), sample sizes are provided in the corresponding figure legends. 
For MTT assays used to assess drug regimen sequence, cells (Molm14 or FLT3-ITD+ patient 
blasts, one replicate each) were plated on Day 0. After an overnight incubation on stroma, cells 
were treated with drug (Day 1) – either a single agent or with both agents simultaneously.  For 
the Molm14 experiments, wells were re-spiked with AZA or DEC on Days 2 and 3 of the 
experiment, and quizartinib or sorafenib were added to wells on Day 3.  MTT reagents were 
added on Day 5, and plates were read on Day 6 at 595 nm with a plate reader (iMark Microplate 
reader, Bio-Rad).  For patient blasts, wells were re-spiked with AZA or DEC on Days 2, 3, and 4 
of the experiment, and the FLT3 inhibitor was added to wells on Day 4.  MTT reagents were 
added on Day 7, and plates were read on Day 8 at 595 nm. 
 
Flow cytometry 
Flow cytometric analysis was performed on Molm14 cells and primary AML blasts as 
described(5). Cell line data reflect a sample size (n = 3). Experiments with primary patient blasts 
reflect data from three separate patient samples and were performed based on patient sample 
availability and cell yield. Cells were treated with quizartinib or sorafenib, DEC and AZA, either 
as single agents or in combination, in the presence and absence of bone marrow stromal cells.  
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Stromal cells were seeded into 6- or 12-well plates.  Leukemia cells were seeded in 6- or 12-well 
plates in the presence or absence of bone marrow stromal cells.  At the appropriate time, 
leukemia cells were harvested from the plates (the stromal cells in each well remain adherent) 
and assayed on a FACSCalibur machine (BD Biosciences) as described(27). 
 
Immunoblotting 
In each well of a 6- or 12-well plate, Molm14 (5 x 106) cells were incubated in RPMI medium in 
the presence or absence of stroma as outlined for each experiment.  After incubation at 37˚C the 
cells were harvested at the appropriate time and analyzed by immunoblotting as described 
previously(26). After cell lysis and prior to running SDS-PAGE, protein concentrations in each 
sample were normalized via the BCA protein assay (Pierce). 
 
Differentiation assay 
FLT3-ITD+ patient blasts (4 x 106) were plated (Day 0) on normal human bone marrow stroma 
growing in 6-well plates. Blasts were incubated on stroma overnight before adding drug the 
following day (Day 1).  DEC and AZA were added to plates every day and quizartinib or 
sorafenib was added every five days.  On Day 12, cells were harvested off stroma and analyzed 
by flow cytometry with a BD FACSCalibur and by Western blotting for FLT3.  
 
DNA sequencing 
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Libraries were prepared using the Agilent SureSelect-XT Target Enrichment Kit. Briefly, 1 µg of 
DNA was fragmented to a size of 250-300 bp. Each library was then hybridized to a SureSelect 
custom panel 2.8M bait set (Agilent) according to the manufacturer's protocol. The custom panel 
was designed as a clinical leukemia panel, and covers 637 genes important in oncogenesis. The 
gene manifest is available upon request. Captured samples were clustered in groups of five on a 
cBOT system and sequenced on a single lane of a PE-flow cell on a HiSeq2500 (Illumina), using 
a 2 × 150 bp PE protocol. All reads were aligned to the human genome (GRCh37/hg19), using 
the Burrows–Wheeler alignment (BWA) algorithm. The final BAM file was used for variant 
calling with our custom variant caller pipeline. The sequencing coverage exceeded 300 reads in 
more than 94% of all regions.  
 
Statistical analysis 
Data obtained from independent experiments on multiple samples were reported as the mean ± 
SEM.  Significance levels were determined by Student’s t-test analysis.  Synergy calculations 
were performed using CalcuSyn software (Biosoft, Cambridge, UK). 
 
 
Results 
The combination of FLT3 inhibition and DNMT inhibition results in synergistic cytotoxicity 
Our previous work indicated that mesenchymal stromal cells derived from normal human bone 
marrow conferred on leukemia cells a protective effect against FLT3 inhibition, and represented 
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a better alternative to suspension culture for modeling responses to cytotoxic agents(5, 28). The 
Molm14 cell line is an AML cell line derived from a patient harboring a FLT3/ITD 
mutation(29). We exposed Molm14 cells to different concentrations of inhibitors, alone and in 
combination (simultaneous treatment) in the presence or absence of bone marrow stromal cells.  
Quizartinib was added at time = 0 on day 0 whereas AZA or DEC were added at time = 0 and 24 
hours due to the reported short half-life of these agents(23). After 48 hours, we performed MTT 
assays to measure cell proliferation and reduction in cell viability. As shown in Figure 1A, 
growth inhibitory effects were observed for FLT3 and DNMT inhibition, both in single and 
combined treatment.  In line with our previous findings, stromal cells consistently conferred 
protection against the cytotoxic effects of all treatments (Figure 1A).  The combination of either 
AZA or DEC with quizartinib was particularly synergistic at impeding growth in the setting of 
stromal co-culture.  These experiments were repeated using 3 nM sorafenib in place of 1 nM 
quizartinib, and the results were essentially the same (data not shown).  This is consistent with 
our previous findings of sorafenib exerting a similar cytotoxic effect as quizartinib(5, 28). 
 
In order to investigate the basis for this cytotoxicity, we incubated Molm14 cells with 
quizartinib, DEC or AZA in single or combined treatment mode in the presence or absence of 
stromal cells, and after 48 hours, the cells were harvested, labeled with Annexin V, and analyzed 
by flow cytometry (Figure 1B).  Combined treatment of Molm14 cells with quizartinib and DEC 
or AZA for 48 hours did not result in a higher level of apoptosis inducing-effects when compared 
to single agent treatment.  In the presence of stroma, AZA conferred more pro-apoptotic effects 
than DEC, but the effects of both agents were modest.  While the pro-apoptotic effects of AZA 
and quizartinib were similar in the absence of stroma, AZA induced significantly more induction 
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of apoptosis than quizartinib when stromal cells were present.  These findings imply that the 
synergistic effect of FLT3 inhibition and DNMT inhibition on growth inhibition is not 
exclusively mediated through a synergistic induction of apoptosis. 
 
We next wished to confirm that the synergistic cytotoxicity we observed with combined FLT3 
and DNMT inhibition in Molm14 cells could be reproduced in primary cells isolated from AML 
patients harboring FLT3/ITD mutations.  Because blasts isolated from newly diagnosed versus 
relapsed FLT3/ITD AML patients display differential responses to FLT3 inhibition in vitro (e.g. 
samples from relapsed patients are more responsive)(26), we tested blasts from both types of 
patients.  The anti-leukemic effects of quizartinib, DEC and AZA against primary AML blasts 
derived from newly diagnosed and relapsed FLT3/ITD mutated patients were assessed after 48 
hours of exposure in culture in the presence of stroma.  Consistent with the data obtained in the 
Molm14 cell line, MTT assays indicated that each DEC and AZA exerted dose dependent 
cytotoxicity as shown in Figure 2.  As expected, quizartinib demonstrated significantly greater 
growth inhibition in relapsed compared to newly diagnosed samples, which is consistent with the 
greater addiction to FLT3 signaling commonly observed in relapsed samples.  Furthermore, in 
both newly diagnosed and relapsed samples, AZA demonstrated significantly greater 
cytotoxicity than DEC as depicted in Figure 2 (A and C versus B and D). 
Simultaneous versus sequential treatment 
Our previous studies suggested that the sequence of administration of FLT3 inhibitors and 
chemotherapy was important for maximizing cytotoxic effect(27). However, DNMT inhibitors 
have a mechanism of action that is unique from conventional DNA-damaging agents (e.g., 
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anthracyclines) in that they induce epigenetic changes.  Therefore, we wished to determine if the 
sequence of administration (e.g., simultaneous or sequential) of FLT3 inhibitors and DNMT 
inhibitors influenced the cytotoxic effect.  We first confirmed that for both AZA and DEC, pre-
treatment with FLT3 inhibition was the least effective sequence for inducing apoptosis (Figure 3) 
and thus focused on 2 approaches: 1) simultaneous exposure to AZA or DEC and quizartinib; 
and 2) exposure to AZA or DEC followed by quizartinib.  These dose response studies were 
carried out using Molm14 cells cultured on bone marrow stroma, combination indices were 
calculated by median effect analysis, and the results are shown in Table 1.  In contrast to what 
we expected, the most effective sequence for either AZA or DEC with quizartinib was 
simultaneous, not sequential, with CI values indicating additive or synergistic effects at most 
concentrations.  Extending these studies to primary AML cells, a similar pattern was observed 
(Table 2), in that simultaneous treatment was the most effective way to combine the agents.  In 
fact, DEC or AZA followed by quizartinib was mostly antagonistic with this primary sample. 
 
DNMT and FLT3 inhibition induce differentiation 
According to the results of the assays for cell proliferation and apoptosis described above, 
simultaneous treatment of FLT3/ITD AML cells with quizartinib and either AZA or DEC results 
in synergistic inhibition of growth, with induction of apoptosis contributing to this effect.  
Because both classes of agents are associated with the induction of differentiation, we wished to 
determine if differentiation could be contributing to the overall cytotoxic effect as well.  Because 
the simultaneous treatment model yielded the greatest magnitude of cytotoxicity, we focused on 
this approach, using a primary FLT3/ITD AML sample (collected at relapse) cultured on stroma.   
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The degree of cytotoxic effect induced by these combinations at 12 days rendered it problematic 
to identify differentiated cells by morphology (there were too few cells remaining to quantify a 
differentiation effect by microscopy).  However, we analyzed blasts for expression of cell 
surface markers of differentiation following treatment with single agent AZA, DEC, or 
quizartinib, or the combination (Figure 4A).  Using loss of CD34, CD117, and CD11b 
expression as markers of differentiation, we found that all 3 agents induced differentiation of this 
sample after cells were exposed for 12 days.  However, combination therapy did not appear to 
result in synergy, or even additivity, although median effect analysis was not performed because 
we did not carry out a dose-response experiment.  We looked at these markers in a second 
primary sample (Supplemental Figure 1) and also saw a differentiation effect. However, for this 
sample, the differentiation effects of AZA were much more prominent than those of the other 
agents. This variation is most likely due to the patient-to-patient differences that would be 
expected in experiments utilizing primary blasts. This experiment was repeated with a third 
primary sample, with similar results (not shown), although down-regulation of CD117 was not 
prominent until Day 15 of exposure. 
 
If leukemia cells are undergoing terminal myeloid differentiation in response to either FLT3 or 
DNMT inhibition, expression of the FLT3 receptor should be down-regulated as a part of that 
process, as we have previously observed(5). To confirm this, we carried out immunoblots of total 
and phosphorylated FLT3 in the cells used in the above experiment shown in Figure 4A.  As 
shown in Figure 4B, expression of both phosphorylated and total FLT3 is nearly absent in cells 
treated with single or combination therapy. We examined two other markers of neutrophil 
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differentiation, lactoferrin and matrix metalloproteinase-9 (not shown); however, the 
immunoblots for these markers did not show any clear trends towards differentiation. 
 
The combination of sorafenib and 5-azacitidine induces differentiation in vivo 
Both quizartinib and sorafenib have been used in combination with 5-azacitidine in single arm 
clinical trials(20, 25). However, the endpoints of these trials were clinical, and correlative 
laboratory studies did not focus on any in vivo differentiation that might have been induced by 
this combination.  A 60 year old woman with FLT3/ITD AML in first remission was scheduled 
for an allogeneic transplant, but relapsed just prior to starting preparative chemotherapy.  She 
was enrolled on a trial of PLX3397, a novel FLT3 inhibitor(30), but was deemed unresponsive 
after 2 cycles.  We therefore opted to treat her with sorafenib (off-label, off-protocol) 400 mg 
orally twice daily continuously, plus 5-azacitidine 75 mg/m2 IV days 1-7 of each 28 day cycle of 
sorafenib, as per the published protocol(20). We performed mutation analysis on her peripheral 
blood cells at the start of therapy, and at different time points during therapy (Figure 5).  Each of 
her first 2 cycles of 5-azacitidine were followed with a surge of neutrophils which harbored the 
FLT3/ITD mutation noted to be in blasts at the start of therapy.  After the third cycle of 5-
azacitidine, the circulating neutrophils increased more gradually, and the FLT3/ITD mutation 
was no longer detectable in these cells.  A bone marrow biopsy confirmed a complete remission 
by IWG standards. 
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Discussion 
In the present study, we used in vitro models to assess the effects of either DEC or AZA 
combined with Quiz on the FLT3/ITD+ cell line Molm14 and primary cells derived from newly 
diagnosed and relapsed patients.  Consistent with our previous studies, bone marrow stromal 
cells conferred significant protection against the effects of all treatments(28). Our data shows 
that all 3 agents have cytotoxic activity against FLT3/ITD mutated cells within the tested dose 
range. The synergistic cytotoxic effect observed with the combination of FLT3 inhibition and 
DNMT inhibition was due to the induction of immediate apoptosis as well as terminal myeloid 
differentiation.  The FLT3 allelic burden for these differentiated blasts were not analyzed post-
treatment, as the blast population used in our experiments were peripheral blasts that most likely 
had very few non-malignant stem/progenitor cells in them. Thus, normal hematopoiesis would 
not occur within the context of our experiments, and the allelic burden would not change, as 
shown by Sexauer et al.(5). The efficacy of this combination is already apparent from clinical 
studies, and the case presented in this report illustrates that the in vitro processes we have 
investigated can occur in vivo.  Our data, therefore, establishes a mechanistic rationale for this 
treatment regimen. 
 
The differentiation induced by FLT3 inhibition seems to be a class effect, as it has been observed 
with multiple different TKIs, both in vitro and in vivo.  The choice of which demethylating agent 
should be combined with a FLT3 inhibitor is perhaps less clear.  Our data would suggest that 
AZA is the better choice, with the obvious caveat that in vitro studies have significant limitations 
in predicting responses in vivo.  Both in the presence and absence of stroma, AZA was 
17 
 
significantly more cytotoxic than equimolar concentrations of DEC, at least from the standpoint 
of inducing growth inhibition and apoptosis. This differential effect in anti-leukemic activity 
may at least in part be due to the additional incorporation of AZA into RNA, and the resulting 
interference with nucleic acid and protein synthesis, whereas DEC is solely incorporated into 
DNA. Indeed, although DEC and AZA are structurally related and share related mechanisms of 
action, differences in their potency have been reported in clinical and preclinical studies(18, 22, 
23). Viability assays on AML cell lines demonstrated that AZA is much more potent that DEC 
whereas a higher level of activity has been reported for DEC when assessing molecular 
endpoints such as incorporation into DNA, DNA hypomethylation and DNA damage(31). Both 
drugs exert their anti-leukemic activity via the regulation of multiple, partially interconnected 
mechanisms, ranging from DNA methylation, gene expression, cell cycle progression and 
differentiation to different modes of cell death.  While some of these mechanisms are shared or 
overlapping, others are specific to each drug, and yet other mechanisms have not been unveiled 
to date.  Clearly, our data and that of others indicate that the effects of DEC and AZA are dose 
and time dependent and therefore offer a broad range of therapeutic options, including long term 
treatment courses at low concentrations either as single modality or in combination with other 
agents(32, 33). We are currently exploring the mechanism of cooperation between FLT3 and 
DNMT inhibition, focusing on alterations in expression of myeloid-relevant genes.  For example, 
DNMT inhibition might lead to the reversal of aberrant methylation in the promoter regions of 
myeloid transcription factors(34). In the setting of cell cycle arrest induced by FLT3 inhibition, 
combined with and the presence of stromal-derived cytokines, de-methylation could enhance 
induction of differentiation. An interesting point to note is that all nine patient samples contained 
mutations in genes that are involved in epigenetic modifications (i.e. IDH1, WT1). The role of 
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these genes in affecting DNA methylation could explain the response of these patient blasts to 
the hypomethylating agents. The prevalence of these genes in AML suggests that a combination 
therapy of FLT3 inhibitors and demethylating agents could be broadly applied to treating AML 
patients.  
 
The prognosis for AML patients harboring a FLT3/ITD mutation remains generally poor, and 
while younger patients with FLT3/ITD AML seem to benefit from allogeneic transplant, this is 
frequently not an option for many older patients.  Our study demonstrates that the combination of 
a hypomethylating agent and FLT3 inhibitor is a potentially important new therapeutic regimen 
for FLT3/ITD+ AML, and further suggests that this regimen could be used in patients of any age 
group. 
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Figure Legends 
Figure 1: Combined treatment results in synergistic anti-leukemic effects in the presence 
and absence of stroma.  Molm14 cells were cultured in drug supplemented medium at the 
indicated concentrations, both in the presence and absence of stroma. Growth inhibition was 
assessed after 48 hours using MTT cell viability assays (A). Combination Index (CI) values are 
shown for each experiment.  The mean ± SEM is based on replicate experiments (n= 3-12). 
Significant changes in the percentage of growth inhibition are indicated (*p<.05), (**p<.01), 
(***p<.001). Flow cytometry was used to measure apoptosis in these cells via Annexin 
V/propidium iodide and quantified as shown in (B). 
 
Figure 2: Combined treatment confers additive to synergistic growth inhibitory effects on 
primary FLT3 positive AML cells. Primary blasts derived from newly diagnosed (A, B) and 
relapsed (C, D) FLT3/ITD+ AML patients were incubated in drug supplemented medium at the 
indicated concentrations in the presence of stroma. Growth inhibition was assessed after 48 hours 
using the MTT assay. The mean ± SEM is based on replicate experiments (n= 3). Significant 
changes in the percentage of growth inhibition are indicated (*p<.05), (**p<.01), (***p<.001).  
 
Figure 3: The sequence of administration for combining FLT3 inhibitors and DNMT 
inhibitors is crucial. Molm14 cells were cultured in drug supplemented medium in suspension. 
The different drugs (the FLT3 inhibitor quizartinib and the two DNMT inhibitors) were given in 
either sequentially or simultaneously: white bars denote sequential treatment with Quiz first 
followed by DEC/AZA, black bars represent sequential treatment with DEC/AZA first followed 
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by Quiz, and gray bars denote simultaneous administration of both types of drugs. Following 
pretreatment, cells were incubated for an additional 48 hours before being harvested for flow 
cytometry analysis with Annexin V/propidium iodide staining. The mean ± SEM is based on 
replicate experiments (n= 3). Significant changes in the percentage of growth inhibition are 
indicated (*p<.05), (**p<.01), (***p<.001). 
 
Figure 4: Treating FLT3/ITD blasts with a FLT3 inhibitor, a DNMT inhibitor, or both 
simultaneously induces differentiation. FLT3/ITD primary blasts co-cultured on stroma were 
treated with drug at the specified concentrations. Cells were harvested on Day 12 after starting 
drug treatment, stained for the cell-surface markers CD34, CD117, and CD11b, and analyzed via 
flow cytometry (A). The remaining cells were lysed and analyzed via immunoblotting (B). 
 
Figure 5. Peripheral blood absolute blast and neutrophil count of patient treated with 5-
azacitidine and sorafenib.  The patient was treated continuously with sorafenib 400 mg twice 
daily beginning on Day 1, and with 5-azacitidine 75 mg/meter-squared IV daily for 7 days during 
the time periods indicated by black bars.  At each of the indicated time points, the cellular 
fraction from the peripheral blood was analyzed for the presence of the FLT3/ITD mutation. 
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Figure 5 
Simultaneous treatment:
Decitabine Azacytidine
0.2 uM 0.5 uM 1 uM 2 uM 0.2 uM 0.5 uM 1 uM 2 uM
1 nm Quiz 0.172 * 0.19 * 0.158 * 0.166 * 0.431  * 0.487  * 0.652 * 0.986
5 nM Quiz 0.555 * 0.53 * 0.553 * 0.556 * 0.727 * 0.716 * 0.907 1.269
10 nM Quiz 1.1 1.117 1.24 1.029 1.266 1.4 1.474 1.787
Sequential treatment:
Decitabine Azacytidine
0.2 uM 0.5 uM 1 uM 2 uM 0.2 uM 0.5 uM 1 uM 2 uM
1 nm Quiz 1.079 0.958 0.466 * 0.433 * 1.711 1.219 0.873 * 1.014
5 nM Quiz 0.647 * 0.63 * 0.601 * 0.625 * 0.919 0.1008 1.088 1.218
10 nM Quiz 1.29 1.178 1.145 1.072 1.538 1.545 1.505 1.909
* denotes synergy (0 < CI < 0.9)
Table 1
Simultaneous treatment:
Decitabine Azacytidine
0.2 uM 0.5 uM 1 uM 2 uM 0.2 uM 0.5 uM 1 uM 2 uM
5 nm Quiz 0.514 * 0.945 0.744 * 0.618 * 0.459 0.401 * 0.469 * 0.753 *
10 nM Quiz 0.655 * 0.943 0.328 * 0.43 4* 0.495 * 0.467 * 0.55 * 0.715 *
20 nM Quiz 0.333 * 0.465 * 0.674 * 0.51 * 1.399 0.842 * 0.532 * 0.741 *
Sequential treatment:
Decitabine Azacytidine
0.2 uM 0.5 uM 1 uM 2 uM 0.2 uM 0.5 uM 1 uM 2 uM
5 nm Quiz 5.31 4.725 1.913 0.953 3.731 1.152 0.594 * 0.781 *
10 nM Quiz 5.906 3.874 1.087 0.78 * 3.919 2.518 0.795 * 1.053
20 nM Quiz 3.891 2.499 1.219 2.401 9.797 2.042 0.635 * 0.737 * 
* denotes synergy (0 < CI < 0.9)
Table 2
